Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 1
2013 3
2014 2
2015 1
2016 1
2017 2
2018 1
2020 1
2021 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Overexpression of p53R2 is associated with poor prognosis in lung sarcomatoid carcinoma.
Chen J, Xiao Y, Cai X, Liu J, Chen K, Zhang X. Chen J, et al. BMC Cancer. 2017 Dec 15;17(1):855. doi: 10.1186/s12885-017-3811-6. BMC Cancer. 2017. PMID: 29246119 Free PMC article.
BACKGROUND: This study aimmed to evaluate the expression of p53-inducible RR small subunit 2 homologue (p53R2) in Lung sarcomatoid carcinoma (LSC) and its association with clinicopathological parameters and prognosis. ...Further multivariate analysis indicate …
BACKGROUND: This study aimmed to evaluate the expression of p53-inducible RR small subunit 2 homologue (p53R2) in Lung sarcomatoid …
GATA3 is a useful immunohistochemical marker for distinguishing sarcomatoid malignant mesothelioma from lung sarcomatoid carcinoma and organizing pleuritis.
Piao ZH, Zhou XC, Chen JY. Piao ZH, et al. Virchows Arch. 2021 Aug;479(2):257-263. doi: 10.1007/s00428-021-03048-y. Epub 2021 Feb 11. Virchows Arch. 2021. PMID: 33570661
Sarcomatoid malignant mesothelioma (SMM) tends to occur in the pleura and is morphologically similar to lung sarcomatoid carcinoma (LSC) and organizing pleuritis (OP). Because SMM often does not express mesothelial markers, it is very difficult to distinguish …
Sarcomatoid malignant mesothelioma (SMM) tends to occur in the pleura and is morphologically similar to lung sarcomatoid ca …
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Sun LL, Wu JY, Wu ZY, Shen JH, Xu XE, Chen B, Wang SH, Li EM, Xu LY. Sun LL, et al. Int J Cancer. 2015 Mar 15;136(6):E569-77. doi: 10.1002/ijc.29211. Epub 2014 Sep 24. Int J Cancer. 2015. PMID: 25220908 Free PMC article.
GASC1, member of the histone demethylases affecting heterochromatin formation and transcriptional repression, has been found to be dysregulation in many types of cancers including breast cancer, prostate cancer, metastatic lung sarcomatoid carcinoma, and leuk …
GASC1, member of the histone demethylases affecting heterochromatin formation and transcriptional repression, has been found to be dysregula …
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y. Amatya VJ, et al. Mod Pathol. 2017 May;30(5):672-681. doi: 10.1038/modpathol.2016.181. Epub 2017 Jan 27. Mod Pathol. 2017. PMID: 28128276 Free article.
We performed whole gene expression analysis of formalin-fixed paraffin-embedded tissue from sarcomatoid mesothelioma and lung sarcomatoid carcinoma and observed significant differences in the expression of MUC4 and other genes between sarcomatoid mesot …
We performed whole gene expression analysis of formalin-fixed paraffin-embedded tissue from sarcomatoid mesothelioma and lung sarc …
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages.
Vieira T, Antoine M, Hamard C, Fallet V, Duruisseaux M, Rabbe N, Rodenas A, Cadranel J, Wislez M. Vieira T, et al. Lung Cancer. 2016 Aug;98:51-58. doi: 10.1016/j.lungcan.2016.05.013. Epub 2016 May 21. Lung Cancer. 2016. PMID: 27393506 Free article.
By characterizing intra-tumoral immune infiltration and evaluating PD-L1 expression, it could be possible to predict the efficacy of these new treatments. MATERIALS AND METHODS: From 1997 to 2013, data from all patients with SC who underwent lung resection was collected. . …
By characterizing intra-tumoral immune infiltration and evaluating PD-L1 expression, it could be possible to predict the efficacy of …
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
Gendarme S, Matton L, Antoine M, Kerrou K, Ruppert AM, Epaud C, Cadranel J, Fallet V. Gendarme S, et al. Lung Cancer. 2021 Feb;152:94-97. doi: 10.1016/j.lungcan.2020.12.022. Epub 2020 Dec 21. Lung Cancer. 2021. PMID: 33360808
METHODS: We present a patient with strong ALK and PD-L1 positive IHC expression lung sarcomatoid carcinoma with initial life-threatening disease progression after beginning ALK TKI. ...Although lung carcinoma with ALK rearrangement seems to be not sensitive t …
METHODS: We present a patient with strong ALK and PD-L1 positive IHC expression lung sarcomatoid carcinoma with initial …
The value of biomarkers in patients with sarcomatoid carcinoma of the lung: molecular analysis of 33 cases.
Jiang X, Liu Y, Chen C, Zhan Z, Yan Q, Guo Y, Wang Q, Li K. Jiang X, et al. Clin Lung Cancer. 2012 Jul;13(4):288-96. doi: 10.1016/j.cllc.2011.11.004. Epub 2011 Dec 13. Clin Lung Cancer. 2012. PMID: 22169481
To better understand the prognosis of sarcomatoid carcinoma of the lung, the correlation between several biomarkers (ERCC1 [excision repair cross-complementation group 1] and EGFR [epidermal growth factor receptor] expression, EGFR and KRAS mutations, and EGFR copy number) and cl …
To better understand the prognosis of sarcomatoid carcinoma of the lung, the correlation between several biomarkers (ERCC1 [excision repair …
EML4-ALK translocation in both metachronous second primary lung sarcomatoid carcinoma and lung adenocarcinoma: a case report.
Alì G, Proietti A, Niccoli C, Pelliccioni S, Borrelli N, Giannini R, Lupi C, Valetto A, Bertini V, Lucchi M, Mussi A, Fontanini G. Alì G, et al. Lung Cancer. 2013 Aug;81(2):297-301. doi: 10.1016/j.lungcan.2013.03.016. Epub 2013 May 10. Lung Cancer. 2013. PMID: 23664446
It represents one of the newest molecular targets in NSCLC. We report on the case of a metachronous second primary lung sarcomatoid carcinoma after resection of lung adenocarcinoma both with ALK translocation, in a non-smoking patient. ...To assess the clonal …
It represents one of the newest molecular targets in NSCLC. We report on the case of a metachronous second primary lung sarcomatoi …
Initial presentation of lung sarcomatoid carcinoma as a metastatic lesion in the mandibular gingiva.
Park JY, Kim HS, Zo JI, Lee S, Choi SW. Park JY, et al. J Periodontol. 2006 Apr;77(4):734-7. doi: 10.1902/jop.2006.050137. J Periodontol. 2006. PMID: 16584358
Occasionally, an oral metastatic lesion may be the preliminary clinical feature observed before the diagnosis of the primary tumor. METHODS: The clinical features of gingival metastasis as an initial presentation of lung sarcomatoid carcinoma are discu …
Occasionally, an oral metastatic lesion may be the preliminary clinical feature observed before the diagnosis of the primary tumor. M …
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Vieira T, Girard N, Ung M, Monnet I, Cazes A, Bonnette P, Duruisseaux M, Mazieres J, Antoine M, Cadranel J, Wislez M. Vieira T, et al. J Thorac Oncol. 2013 Dec;8(12):1574-7. doi: 10.1097/01.JTO.0000437008.00554.90. J Thorac Oncol. 2013. PMID: 24389441 Free article.
At first tumor evaluation, 69% of patients experienced progression, 31% had disease control, and 16.5% had partial response. Partial response was observed in 20% of patients receiving platinum-based CT, and in none of those receiving non-platinum-based CT (p = 0.018). ...
At first tumor evaluation, 69% of patients experienced progression, 31% had disease control, and 16.5% had partial response. Partial respons …
13 results